DelveInsight’s, “Interleukin 8 Receptor Antagonists - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 6+ pipeline drugs in Interleukin 8 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interleukin 8 Receptor Antagonists: Overview
Interleukin-8 (CXCL8) was the first member to be identified of this new family of proinflammatory chemokines that now constitute over 45 members. Chemokines produce their biological effects by interacting with greater than 18 G protein coupled cell surface receptors. A few chemokines bind selectively to a single receptor but other chemokines bind to more than one receptor. CXCL8 belongs to a subgroup of chemokines known as ELR+ chemokines because of the Glu4-Leu5-Arg6 amino acid sequence between positions 4 and 6. Interleukin-8 is a key mediator associated with inflammation where it plays a key role in neutrophil recruitment and neutrophil degranulation. Interleukin-8 secretion is increased by oxidant stress, which thereby cause the recruitment of inflammatory cells and induces a further increase in oxidant stress mediators, making it a key parameter in localized inflammation. IL-8 was shown to be associated with obesity.
The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin 8 Receptor Antagonists R&D. The therapies under development are focused on novel approaches for Interleukin 8 Receptor Antagonists.
This segment of the Interleukin 8 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin 8 Receptor Antagonists Emerging Drugs
Ladarixin: Dompe Farmaceutici
Ladarixin is an investigational, oral, small-molecule that functions as a non-competitive, dual allosteric inhibitor of CXCL8 (IL-8) receptors, CXCR1 and CXCR2. By blocking CXCR1/2 receptors, Ladarixin may prevent inflammation- and immune system-mediated destruction of β-cells in pancreatic islets that is a hallmark of T1D.2 CXCR1/2 inhibition has been shown to prevent and to reverse T1D in mice
AZD 5069: AstraZeneca
AZD5069 is a potent (IC50 0.79nM), CXCR2 selective (>150-fold less potent at CXCR1 and CCR2b receptors; no effect on C5a, LTB4 or fMLP induced CD11b expression), reversible (but time and temperature dependent) antagonist of the human CXCR2 receptor.
Further product details are provided in the report……..
This segment of the report provides insights about the different Interleukin 8 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the Interleukin 8 Receptor Antagonists. The companies which have their Interleukin 8 Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase III include, Dompe Farmaceutici.
DelveInsight’s report covers around 6+ products under different phases of clinical development like
Interleukin 8 Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin 8 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin 8 Receptor Antagonists drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Interleukin 8 Receptor Antagonists: Overview
Pipeline Therapeutics
Therapeutic Assessment
Interleukin 8 Receptor Antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Ladarixin: Dompe Farmaceutici
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AZD 5069: AstraZeneca
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
SX 682: Syntrix Biosystems
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
CPI 182: Corvus Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
Interleukin 8 Receptor Antagonists Key Companies
Interleukin 8 Receptor Antagonists Key Products
Interleukin 8 Receptor Antagonists- Unmet Needs
Interleukin 8 Receptor Antagonists- Market Drivers and Barriers
Interleukin 8 Receptor Antagonists- Future Perspectives and Conclusion
Interleukin 8 Receptor Antagonists Analyst Views
Interleukin 8 Receptor Antagonists Key Companies
Appendix
List of Table
Table 1: Total Products for Interleukin 8 Receptor Antagonists
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Interleukin 8 Receptor Antagonists
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Dompe Farmaceutici
• AstraZeneca
• Syntrix Biosystems
• Ligand Pharmaceuticals
• Aristea Therapeutics
• Corvus Pharmaceuticals
